PGEN PRECIGEN, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1356090 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY109.9%
TTM EPS YoY107.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin21.4%
Net margin15.6%
FCF margin-47.4%
EBITDA margin23.9%
Returns
ROE38.8%
ROA12.7%
ROIC (approx.)23.5%
Asset turnover0.82x
Leverage & solvency
Liabilities / assets60.5%
Debt / equity1.12x
Current ratio5.58x
Interest coverage2.85x
Cash quality & payout
Operating cash flow / net income-3.00x
Accruals ratio50.9%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $74.15M | $54.98M | $23.25M | $4.57M | $2.92M | $856,000 | $1.34M | — |
| R&D expense | $6.63M | $7.28M | $5.64M | $6.99M | $12.38M | $11.49M | $10.48M | — |
| SG&A expense | $22.36M | $22.25M | $21.05M | $17.64M | $23.99M | $16.13M | $12.36M | — |
| Operating income | $38.65M | $22.64M | -$5.99M | -$21.67M | -$34.48M | -$31.76M | -$22.60M | — |
| Interest expense | $3.00M | $2.95M | $2.91M | $2.96M | $902,000 | $0 | $1,000 | — |
| Pretax income | $35.97M | $20.07M | -$7.93M | -$23.50M | -$146.34M | -$26.64M | -$54.15M | -$19.81M |
| Income tax | $200,000 | $0 | $0 | $0 | $0 | $3,000 | $0 | -$87,000 |
| Net income | $35.77M | $20.07M | -$7.93M | -$23.50M | -$146.34M | -$26.64M | -$54.15M | -$19.73M |
| EBITDA | $39.44M | $23.42M | -$4.89M | -$20.53M | -$34.00M | -$31.45M | -$21.97M | — |
| EPS (basic) | 0.10 | 0.06 | -0.02 | — | -1.06 | -0.09 | -0.18 | — |
| EPS (diluted) | 0.08 | 0.05 | -0.02 | — | -1.06 | -0.09 | -0.18 | — |
| Weighted avg. shares (diluted) | 421.16M | 413.69M | 354.29M | — | 307.17M | 296.43M | 293.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.96M | $16.33M | $7.48M | $30.23M | $14.32M | $13.76M | $6.06M | $29.52M |
| Short-term investments | $31.11M | $21.88M | $48.77M | $67.62M | $106.81M | $45.99M | $74.18M | $68.39M |
| Receivables | $96.49M | $71.87M | $26.40M | $3.92M | $580,000 | $327,000 | $751,000 | $926,000 |
| Inventory | $22.91M | $20.25M | $14.72M | $9.58M | $3.06M | — | — | $0 |
| Current assets | $171.76M | $134.38M | $101.67M | $115.23M | $129.60M | $62.76M | $84.60M | $102.41M |
| PP&E, net | $13.29M | $12.80M | $13.22M | $13.76M | $14.81M | $14.70M | $14.67M | $13.83M |
| Goodwill | $15.23M | $15.23M | $15.23M | $15.23M | $15.23M | $15.23M | $19.14M | $19.14M |
| Intangibles | $2.23M | $2.54M | $2.86M | $3.18M | $3.50M | $3.82M | $4.14M | $4.46M |
| Total assets | $212.10M | $170.30M | $138.63M | $155.50M | $171.26M | $101.90M | $128.79M | $145.27M |
| Current liabilities | $30.79M | $29.35M | $21.10M | $37.31M | $32.07M | $23.19M | $23.99M | $21.52M |
| Long-term debt | $94.26M | $93.88M | $93.52M | $93.17M | $92.89M | — | — | $0 |
| Total debt | $94.26M | $93.88M | $93.52M | $93.17M | $92.89M | — | — | $0 |
| Total liabilities | $128.31M | $126.72M | $118.39M | $134.59M | $129.40M | $107.79M | $113.33M | $78.53M |
| Shareholders' equity | $83.79M | $43.58M | $20.23M | $20.91M | $41.87M | -$36.78M | -$14.06M | $38.51M |
| Net debt | $79.30M | $77.55M | $86.04M | $62.94M | $78.57M | — | — | -$29.52M |
| Shares outstanding | 358.54M | 358.01M | 355.90M | 353.91M | 353.81M | 297.85M | 295.14M | 292.87M |
| Cash flow statement | ||||||||
| Operating cash flow | $11.88M | -$17.81M | -$43.83M | -$23.46M | -$29.07M | -$18.98M | -$16.32M | -$8.24M |
| Capital expenditure | $435,000 | $392,000 | $258,000 | $18,000 | $389,000 | $966,000 | $622,000 | $1.03M |
| Free cash flow | $11.45M | -$18.20M | -$44.09M | -$23.48M | -$29.46M | -$19.94M | -$16.95M | -$9.27M |
| Investing cash flow | -$13.97M | $26.69M | $20.97M | $39.87M | -$63.39M | $28.44M | -$6.46M | -$65.37M |
| Financing cash flow | $733,000 | -$33,000 | $109,000 | -$514,000 | $93.01M | -$1.77M | -$679,000 | $78.40M |
| Depreciation & amortization | $793,000 | $782,000 | $1.10M | $1.14M | $485,000 | $312,000 | $629,000 | $661,000 |
| Stock-based compensation | $3.78M | $3.31M | $3.01M | $2.16M | $4.39M | $1.64M | $2.68M | $2.87M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.